Successful Use of Etanercept in a Child with Еnthesitis-Аssociated Аrthritis
https://doi.org/10.31550/1727-2378-2023-22-3-89-91
Abstract
Aim: demonstration of a clinical case of the successful use of etanercept in a child with еnthesitis-аssociated аrthritis.
Key points. Еnthesitis-аssociated аrthritis is one of the clinical variants of juvenile idiopathic arthritis. The initial therapy of еnthesitisаssociated аrthritis includes nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biological disease-modifying drugs, the ineffectiveness of which is an indication for the appointment of genetically engineered drugs, in particular, the inhibitor of tumor necrosis factor-α etanercept.
Conclusion. Currently, for the treatment of еnthesitis-аssociated аrthritis, if the use of NSAIDs and non-biological disease-modifying drugs is ineffective, genetically engineered drugs should be prescribed, in particular etanercept, which allows to achieve drug remission.
Supporting agencies: This study was not supported by any external sources of funding.
About the Authors
A. V. Aksenov
South Ural State Medical University
Russian Federation
Russian Federation
64 Vorovskogo Str., Chelyabinsk, 454092
Е. A. Ivanovskaya
Children's City Clinical Hospital No.8
Russian Federation
Russian Federation
2 Druzhby Str., Chelyabinsk, 454047
References
1. Baranov A.A., Alexeeva E.I. (eds.) Pediatric rheumatology. Atlas. Moscow; 2015. 384 p. (in Russian).
2. Sevostyanov V.K., Zholobova E.S., Novikov A.S. et al. Epidemiological characteristics of rheumatic diseases in children residing in Moscow and antirheumatic therapy. Clinical Practice in Pediatrics. 2019;14(5):95–101. (in Russian). DOI: 10.20953/1817-7646-2019-5-95-101
3. Aksenov A.V., Ivanovskaya Е.А. Successful use of adalimumab in children with juvenile idiopathic arthritis associated with uveitis. Doctor.Ru. 2021;20(10):73–75 (in Russian). DOI:10.31550/1727-2378-2021-20-10-73-75
4. Aksenov A.V., Ivanovskaya Е.А. Successful use of golimumab in a child with juvenile polyrthritis. Doctor.Ru. 2022;21(7):60–62. (in Russian). DOI: 10.31550/1727-2378-2022-21-7-60-62
5. Karaseva A.V., Alexeeva E.I., Dvoryakovskaya T.M. Successful use of etanercept in a patient with polyarticular juvenile idiopathic arthritis with an overview of the predictors of a good response to ongoing therapy. Current Pediatrics. 2017;16(4):321–325. (in Russian). DOI: 10.15690/vsp.v16i4.1779
6. Foeldvari I., Constantin T., Vojinovi J. et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitisrelated arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res. Ther. 2019;21(1):125. DOI: 10.1186/s13075-019-1916-9
7. Ringold S., Angeles-Han S.T., Beukelman T. et al. American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for nonsystemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. (Hoboken). 2019;71(6):717–734. DOI: 10.1002/acr.23870
8. Constantin T., Foeldvari I., Vojinovic J. et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J. Rheumatol. 2016;43(4):816–824. DOI: 10.3899/jrheum.150430
9. Beukelman T., Lougee A., Matsouaka R.A. et al. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr. Rheumatol. 2021;19(1):131. DOI: 10.1186/s12969-021-00625-y
10. Kearsley-Fleet L., Davies R., Lunt M. et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016;55(5):840–847. DOI: 10.1093/rheumatology/kev434
11. Нorneff G., Klein A., Klotsche J. et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res. Ther. 2016;18(1):272. DOI: 10.1186/s13075-016-1170-3
12. Shepherd J., Cooper K., Harris P. et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222. DOI: 10.3310/hta20340
Review
For citations:
Aksenov A.V., Ivanovskaya Е.A. Successful Use of Etanercept in a Child with Еnthesitis-Аssociated Аrthritis. PEDIATRICS. 2023;22(3):89-91. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-3-89-91
Views:
13
Email this article 